Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imexon + gemcitabine
- Development stage
- Unknown
- Lead developer
- Eddingpharm
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Imexon + gemcitabine is a combination of two small molecule chemotherapeutic agents investigated primarily for the treatment of advanced pancreatic adenocarcinoma. Imexon is an aziridine-derived iminopyrrolidone that acts as an inhibitor of ribonucleotide reductase, leading to cell cycle arrest in S phase and induction of apoptosis via mitochondrial dysfunction and oxidative stress. Gemcitabine is a nucleoside analog that also targets ribonucleotide reductase and inhibits DNA synthesis. The combination has shown synergistic cytotoxicity in preclinical models and was evaluated in phase I/II clinical trials for metastatic pancreatic cancer but did not demonstrate improved outcomes over standard therapy[1][3][4][6][8].
- Other names
- Amplimexon (for imexon)
02
Targets
DNA polymerase (nuclear) (DNA Pol)RRM2RRM1
Beyond the preview
Go deeper on Imexon + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imexon + gemcitabine.